EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Trial details
- Registry ID
- NCT06556563
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaNCT06556563 | NovoCure GmbH | Phase 3 | Active not recruiting | 2029-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |